Chemotherapy-induced myelosuppression.
Chemotherapy-induced myelosuppression is the most common dose-limiting and potentially fatal complication of cancer treatment. Prior attempts to lessen chemotherapy-induced myelosuppression have been minimally effective. The new hematopoietic growth factors show promise, especially for patients requiring intensely myelotoxic chemotherapy. However, a cautious approach should be used with growth factors because their clinical uses and how best to apply each use needs to be defined.
Maxwell
M B
MB
Department of Nursing, VA Medical Center, Portland, OR 97207.
Maher
K E
KE
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D001855:Bone Marrow Diseases / Q000097:blood / Q000139:chemically induced* / Q000628:therapy; D002453:Cell Cycle / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006410:Hematopoiesis / Q000187:drug effects*; D016298:Hematopoietic Cell Growth Factors / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use*; D006801:Humans
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors